Who founded Cabaletta Bio?

Cabaletta Bio was founded by Steven Nichtberger, Steven Nichtberger, MD in 2017.

Who are Cabaletta Bio's investors?

Cabaletta Bio's investors include 5AM Ventures, Bain Capital Life Sciences, Deerfield Management Company.

How much funding has Cabaletta Bio raised?

Cabaletta Bio has disclosed $88.3M raised across 2 rounds.

Where is Cabaletta Bio headquartered?

Cabaletta Bio is headquartered in Radnor, US.

Cabaletta Bio

NASDAQ: CABA

Radnor, US · Founded 2017 · Delaware corporation · 199 employees on LinkedIn · 3 known investors

Find your way into Cabaletta Bio

1,903 people in our graph share verified history with the Cabaletta Bio team — schools, employers, funds. One of them is your warm intro.

Aydin Senkutunlockedknows Steven Nichtberger, MD · together at The Wharton School (overlapped)

×8knows the team · via The Wharton School

×2knows the team · via University of Pennsylvania

knows the team · via Merck

Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for patients with autoimmune diseases. Its CABA platform and lead CARTA program center on rese-cel, an investigational CD19-CAR T cell therapy being evaluated in trials across rheumatology, neurology, and dermatology.

Biotech Healthtech

Founders & leadership

Cabaletta Bio was founded in 2017 by Steven Nichtberger and Steven Nichtberger, MD.

Steven Nichtberger inCo-founder, Chairman, & CEOSteven Nichtberger is the founding CEO of Cabaletta Bio, a clinical-stage biotech company developing engineered T cell therapies for autoimmune diseases. He has held senior roles in pharmaceuticals and cellular therapy, including CEO of Tengion and commercial leadership positions at Merck, along with founding experience in healthcare technology ventures.

Steven Nichtberger, MD inCo-founder, Chairman, & CEOSteven Nichtberger, MD, is the founder, chairman, and founding CEO of Cabaletta Bio, a clinical-stage biotechnology company developing engineered T cell therapies for autoimmune diseases. His prior career spans pharmaceuticals, cellular therapy, and medical devices, including senior commercial and strategic leadership at Merck, CEO and President of Tengion, chairman of ControlRad Systems, and partner at GBF Advisors.

Dan GeffkeninSenior Financial Advisor2018–2019

Anup MardainChief Financial Officer

Mark SimonNamed on SEC filing

Board

Brian Daniels inBoard directorVenture Partner at 5AM Ventures

Investors · 3

5AM VenturesBoston · $100K – $4Mvia Brian Daniels · board

Bain Capital Life SciencesBoston

Deerfield Management CompanyreportedNew York

Reported raises · per SEC filings

Form D private placements

$88.3M disclosed across 2 rounds · 2018–2019

▶$50MraisedJan 2019 · 16 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Steven NichtbergerExecutive Officer, Director
Mark SimonDirector
Brian DanielsDirector
Dan GeffkenExecutive Officer

Amount sold: $50M
Sales commissions: $1.1M
Placement agents: Cowen and Company, LLC
First sale: Jan 2019
Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$38.3MraisedDec 2018 · 11 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Mark SimonDirector
Steven NichtbergerExecutive Officer, Director
Brian DanielsDirector
Dan GeffkenExecutive Officer

Amount sold: $38.3M
First sale: Oct 2018
Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events

$259.1Mvaluation at IPOOct 2019 · $11.00/share · 424B4

filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Competitors · 3

by search overlap

Seeking Alpha43 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.

Robinhood39 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.

StockTwits32 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.

Companies competing with Cabaletta Bio for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Cabaletta Bio holder reports 11.6% ownership stake | CABA SEC Filing - Form SCHEDULE 13G/Astocktitan.net · Aug 2026

Frequently asked questions

What does Cabaletta Bio do?: Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for patients with autoimmune diseases. Its CABA platform and lead CARTA program center on rese-cel, an investigational CD19-CAR T cell therapy being evaluated in trials across rheumatology, neurology, and dermatology.
Who founded Cabaletta Bio?: Cabaletta Bio was founded by Steven Nichtberger, Steven Nichtberger, MD in 2017.
Who are Cabaletta Bio's investors?: Cabaletta Bio's investors include 5AM Ventures, Bain Capital Life Sciences, Deerfield Management Company.
How much funding has Cabaletta Bio raised?: Cabaletta Bio has disclosed $88.3M raised across 2 rounds.
Where is Cabaletta Bio headquartered?: Cabaletta Bio is headquartered in Radnor, US.